Literature DB >> 17928207

Cetuximab is effective, but more toxic than reported in the Bonner trial.

H K Lord, E Junor, J Ironside.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17928207     DOI： 10.1016/j.clon.2007.09.003

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  5 in total

1.  pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations.

Authors:  Gabriella Aquino; Giuseppe Pannone; Angela Santoro; Giuseppina Liguori; Renato Franco; Rosario Serpico; Gianluca Florio; Alfredo De Rosa; Marilena Mattoni; Valentina Cozza; Gerardo Botti; Simona Losito; Francesco Longo; Stefania Staibano; Giovanni Cuda; Lorenzo Lo Muzio; Carolina Sbordone; Pantaleo Bufo; Anna Grimaldi; Michele Caraglia; Marina Di Domenico
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

2.  Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab.

Authors:  Naoya Murakami; Seiichi Yoshimoto; Fumihiko Matsumoto; Takao Ueno; Yoshinori Ito; Satoru Watanabe; Kazuma Kobayashi; Ken Harada; Mayuka Kitaguchi; Shuhei Sekii; Kana Takahashi; Kotaro Yoshio; Koji Inaba; Madoka Morota; Minako Sumi; Yutaka Saito; Jun Itami
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-15       Impact factor: 4.553

3.  Rash rates with egfr inhibitors: meta-analysis.

Authors:  N Mittmann; S J Seung
Journal:  Curr Oncol       Date:  2011-04       Impact factor: 3.677

4.  Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.

Authors:  Audrey Rambeau; Radj Gervais; Dominique De Raucourt; Emmanuel Babin; Audrey Emmanuelle Dugué; Carmen Florescu; David Blanchard; Bernard Gery
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-05       Impact factor: 2.503

Review 5.  Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management.

Authors:  K Chanprapaph; V Vachiramon; P Rattanakaemakorn
Journal:  Dermatol Res Pract       Date:  2014-03-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.